Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for OCULAR THERAPEUTIX, INC Common Stock, $0.0001 par value per share (OCUL).
- Disclosed ownership: 9.6%.
- Date of event: 31 Mar 2025.
Deep Track Capital, LP - 31 Mar 2025 SCHEDULE 13G/A Report for OCULAR THERAPEUTIX, INC Common Stock, $0.0001 par value per share (OCUL)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- OCUL
- Shares outstanding
- 160,187,959 shares
- Disclosed Ownership
- 15,458,138 shares
- Ownership
- 9.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 08:45:30 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 9.6% ownership in OCULAR THERAPEUTIX, INC Common Stock, $0.0001 par value per share (OCUL) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 08:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 9.6% | 15,458,138 | 0 | 15,458,138 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 9.6% | 15,458,138 | 0 | 15,458,138 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 9.6% | 15,458,138 | 0 | 15,458,138 | /s/ David Kroin | David Kroin |